The global impact of drug resistance

Clinical Infectious Diseases

Volumn 36, Issue SUPPL. 1, 2003, Pages

  Howard, David H ^a   Scott II, R Douglas ^b   Packard, Randall ^c   Jones, DeAnn ^d  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; ANTIINFECTIVE AGENT; ANTIMALARIAL AGENT; CEFOTAXIME; CEFTRIAXONE; CHLOROQUINE; COTRIMOXAZOLE; ETHAMBUTOL; FANSIDAR; ISONIAZID; METICILLIN; PENICILLIN G; PYRAZINAMIDE; QUININE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN; VANCOMYCIN;

ARTICLE; COST BENEFIT ANALYSIS; DIRECTLY OBSERVED THERAPY; DRUG RESISTANCE; GLOBAL CHANGE; GOVERNMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HUMAN; INFECTION RESISTANCE; MALARIA; MORBIDITY; MORTALITY; OUTCOMES RESEARCH; PHYSICIAN ATTITUDE; PLASMODIUM; PRIORITY JOURNAL; PROBLEM SOLVING; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIA; TREATMENT FAILURE; TUBERCULOSIS;

COMMUNICABLE DISEASES; DRUG RESISTANCE; HEALTH CARE COSTS; HUMANS; TREATMENT FAILURE; WORLD HEALTH;

EID: 0037439526     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/344656     Document Type: Article

References (45)

1. World Health Organization. World health report 1999: making a difference. Geneva: World Health Organization, 1999.
2. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis 1987; 9:1065-78.
3. Phillipson T. Economic epidemiology and infectious diseases. In: Culyer AJ, Newhouse JP, eds. Handbook of health economics. Amsterdam: Elsevier, 2000:1761-97.
4. Philipson T, Posner RA. Private choices and public health: the AIDS epidemic in an economic perspective. Cambridge: Harvard University Press, 1993.
5. Howard DH, Rask KJ. The impact of resistance on antibiotic demand in patients with ear infection. In: Laxminarayan R, Brown G, eds. The economics of resistance. Washington, DC: Resources for the Future (in press).
6. World Health Organization. Antimalarial drug policies: data requirements, treatment of uncomplicated malaria and management of malaria in pregnancy: report of an informal consultation. Geneva: WHO/MAL94 1070, 1994.
7. Phillips M, Phillips-Howard P. Economic implications of resistance to antimalarial drugs. Pharmacoeconomics 1996; 10:225-38.
8. Ellison SF, Hellerstein JK. The economics of antibiotics: an exploratory study. In: Triplett JE, ed. Measuring the prices of medical treatments. Washington, DC: Brookings Institution Press, 1999:118-51.
9. Bonheffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci USA 1997; 94:12106-11.
10. Becerra MC, Bayona J, Farmer PE, et al. Defusing a time-bomb: the challenge of antituberculous drug resistance in Peru. In: The global impact of drug resistant TB. Boston: Harvard Medical School, 1999; 107-26.
11. Boland PB, Kazembe PN, Watkins WM, et al. Malarone-donation programme in Africa. Lancet 1997; 350:1624-5.
12. White NJ. Drug resistance in malaria. Br Med Bull 1998; 54:703-15.
13. Centers for Disease Control and Prevention. Initial therapy for TB in the era of multidrug resistance. MMWR Morb Mortal Wkly Rep 1993; 42(RR-7):1-8.
14. Kotloff KL, Winickoff JP, Ivanoff B, et al. Global burden of Shigella infections: implications for vaccine development and implementation of control strategies. Bull World Health Organ 1999; 77:651-66.
15. Fernandez H. Emergence of antimicrobial resistance in Campylobacter. the consequences for incidence, clinical course, epidemiology and control. In: World Health Organization, ed. The increasing incidence of human campylobacteriosis: report and proceedings of a WHO consultation of experts. Geneva: WHO/CDS/CSR/APH, 2000.4, 2000:33-38.
16. Marcela R, González C, Power P, Vidal MC, Gutkind G. Third-generation cephalosporin resistance in Shigella sonnei, Argentina. Emerg Infect Dis 2001; 7:442-3.
17. Davis MA, Hancock DD, Besser TE, et al. Changes in antimicrobial resistance among Salmonella enterica serovar typhimurium isolates from humans and cattle in the northwestern United States, 1982-1997. Emerg Infect Dis 1999; 5:802-6.
18. Dunne EF, Fey, PD, Kludt P, et al. Emergence of domestically acquired ceftriaxone-resistant Salmonella infections associated with AmpC β-lactamase. JAMA 2000; 284:3151-6.
19. World Health Organization. Guidelines for the control of epidemics due to Shigella dysenteriae type 1. Geneva: WHO/CDR/95.4, 1999.
20. Abramowicz M. The choice of antibacterial drugs. Med Lett Drugs Ther 1999; 41:95-104.
21. Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M, Jones RN. World-wide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2002; 32(Suppl 2):S81-93.
22. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Clin Infect Dis 2000; 31:347-82.
23. US Department of Health and Human Services, National Center for Health Statistics. National Hospital Ambulatory Medical Care Survey, 1997. ICPSR version. Hyattsville, MD: US Department of Health and Human Services, National Center for Health Statistics [producer], 1999. Ann Arbor, MI: Inter-university Consortium for Political and Social Research, 1999.
24. US Department of Health and Human Services, Agency for Healthcare Research and Quality. Medical expenditure panel survey, 1997. Rockville, MD: US Department of Health and Human Services, Agency for Healthcare Research and Quality, 1997.
25. US Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria. OTA-H-629. Washington, DC: US Government Printing Office, 1995.
26. Rubin RJ, Harrington CA, Poon A, et al. The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999; 5:9-17.
27. Abramson MA, Sexton DJ. Nosocomial methicillin-resistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999; 20:408-11.
28. Edmond MB, Ober JF, Dawson JD, Weinbaum DL, Wenzel RP. Vancomycin-resistant enterococcal bacteremia: natural history and attributable mortality. Clin Infect Dis 1996; 23:1234-9.
29. Song X, Plaut D, Karafil L, Perl T. Vancomycin-resistant enterococci nosocomial bloodstream infections: the attributable mortality, length of stay, and extra costs [abstract]. In: Program and Abstracts of the 37th Annual Meeting of the Infectious Diseases Society of America (Alexandria). Philadelphia, PA: Infectious Diseases Society of America, 1999:18-21.
30. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745-51.
31. Montecalvo MA, Jarvis WR, Uman J, et al. Costs and savings associated with infection control measures that reduced transmission of vancomycin-resistant enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001; 22:437-42.
32. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158:522-7.
33. Soufir L, Timsit JF, Mahe C, Carlet J, Regnier B, Chevret S. Attributable morbidity mortality of catheter-related septicemia in critically ill patients: a matched, risk-adjusted, cohort study. Infect Control Hosp Epidemiol 1999; 20:396-401.
34. Shay DK, Maloney SA, Montecalvo M, et al. Epidemiology and mortality risk of vancomycin-resistant enterococci bloodstream infections. J Infect Dis 1995; 172:993-1000.
35. Harbarth S, Rutschmann O, Sudre P, Pittet D. Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998; 158:182-9.
36. Howard D, Cordell R, McGowan JE, Packard RM, Scott RD, Solomon SL. Measuring the costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention - Emory workshop. Clin Infect Dis 2001; 33:1573-8.
37. McGowan JE. The economic impact of antibiotic resistance. Emerg Infect Dis 2001; 7:286-91.
38. Phelps DE. Bug/drug resistance. Med Care 1989; 27:194-203.
39. Murray CJL, Lopez A. The global burden of disease: a comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Geneva: World Health Organization and the World Bank, 1997.
40. Farmer PE, Kononets AS, Borisov SE, et al. Recrudescent TB in the Russian Federation. In: The global impact of drug resistant TB. Boston: Harvard Medical School, 1999:39-84.
41. Weyer K, Fourie PB, Nardell EA. A noxious synergy: TB and HIV in South Africa. In: The global impact of drug resistant TB. Boston: Harvard Medical School, 1999:127-48.
42. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with TB: common errors and their association with the acquisition of drug resistance. JAMA 1993; 270:65-8.
43. Friedan TR, Fujiwara PI, Washko RM, Hamburg MA. Tuberculosis in New York City - turning the tide. N Engl J Med 1995; 333:229-33.
44. Trape JF, Pison G, Preziosi MP, et al. Impact of chloroquine resistance on malaria mortality. Life Sci 1998; 321:689-97.
45. Alliance for the Prudent Use of Antibiotics. Antibiotic resistance: synthesis of recommendations by expert policy groups. Geneva: World Health Organization. WHO/CDS/CSR/DRS/2001.10, 2001.